快樂小藥師 Im pharmacist nichts glücklich

September 22, 2010 — The US Food and Drug Administration (FDA) today announced approval of fingolimod (Gilenya, Novartis), the first of the long-anticipated oral treatments for multiple sclerosis (MS). Fingolimod is approved to reduce relapses and delay disability progression in patients with relapsing forms of MS, an FDA release notes.

Expert Interview With Jack E. Ansell, MD

Linda Brookes, MSc

By Fran Lowry

Medscape Medical News

Acetaminophen Use in Adolescents May Double Risk for Asthma

News Author: Laurie Barclay, MD
CME Author: Penny Murata, MD

Roxanne Nelson

Authors and Disclosures

Posted: 06/21/2010

 今天來練習一下抗潰瘍藥物吧

先來個前測：

1.Which of these proton-pump inhibitors are not affected by food intake?

A.Esomeprazole and omeprazole

B.Pantoprazole and rabeprazole

C.Dexlansoprazole and pantoprazole

D.Dexlansoprazole and lansoprazole

2.On the basis of data after 8 weeks of FDA-approved doses, which of these proton-pump inhibitors has been shown to be superior to omeprazole for the healing of erosive esophagitis?

A.Esomeprazole

B.Immediate-release omeprazole

C.Dexlansoprazole

D.Pantoprazole

選好了嗎？接下來先上個課